Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Samuel J Hong"'
Publikováno v:
Journal of Oncology Practice. 14:e683-e691
Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineopl
Autor:
Federico Felizzi, Samuel J Hong, Ibou Dieye, Anthony Masaquel, Keith A. Betts, Mathias Schulz, Jia Li
Publikováno v:
Blood. 136:3-3
Introduction Polatuzumab vedotin (pola), a first-in-class CD79b-targeted antibody-drug conjugate, was recently approved by the United States (US) Food and Drug Administration (June 2019) in combination with bendamustine-rituximab (BR) for the treatme